Brokers Set Expectations for Opus Genetics FY2030 Earnings

Key Points

• Brookline Capital Markets forecasts Opus Genetics will earn $0.62 per share in FY2030, a sharp contrast with the current-year consensus estimate of a $1.09 loss per share.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $10.69 price target, although ratings range from “Strong Buy” to “Strong Sell.”
• Despite longer-term profitability expectations, Opus Genetics remains financially challenged: its latest quarter showed a $0.14-per-share loss, only $0.76 million in revenue, and deeply negative margins and return on equity.

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Research analysts at Brookline Capital Markets issued their FY2030 earnings estimates for shares of Opus Genetics in a research note issued to investors on Monday, August 10th. Brookline Capital Markets analyst K. Raja expects that the company will earn $0.62 per share for the year. The consensus estimate for Opus Genetics' current full-year earnings is ($1.09) per share.

A number of other equities analysts have also issued reports on the company. Zacks Research lowered Opus Genetics from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Citizens Jmp reaffirmed a "market outperform" rating and set a $11.00 price objective on shares of Opus Genetics in a research note on Monday, June 15th. Wall Street Zen raised Opus Genetics from a "strong sell" rating to a "sell" rating in a research report on Saturday. Leerink Partners began coverage on Opus Genetics in a research note on Thursday, May 21st. They issued an "outperform" rating and a $10.00 target price on the stock. Finally, Citigroup started coverage on Opus Genetics in a report on Tuesday, April 28th. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.69.

Opus Genetics Stock Performance

Shares of NASDAQ:IRD opened at $3.88 on Wednesday. The company has a 50-day simple moving average of $3.80 and a 200-day simple moving average of $4.14. Opus Genetics has a one year low of $1.04 and a one year high of $5.81. The stock has a market capitalization of $320.68 million, a price-to-earnings ratio of -2.87 and a beta of 0.59.

Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%.

Institutional Trading of Opus Genetics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Occudo Quantitative Strategies LP purchased a new stake in Opus Genetics during the fourth quarter worth about $25,000. Stoneridge Investment Partners LLC purchased a new position in Opus Genetics in the second quarter valued at about $47,000. State of Wyoming purchased a new position in Opus Genetics in the second quarter valued at about $65,000. Virtu Financial LLC acquired a new stake in shares of Opus Genetics during the 4th quarter valued at approximately $34,000. Finally, Johnson Investment Counsel Inc. acquired a new stake in shares of Opus Genetics during the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 14.97% of the company's stock.

Insiders Place Their Bets

In other Opus Genetics news, Director Fighting Blindness Foundation sold 1,700,000 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $4.35, for a total value of $7,395,000.00. Following the completion of the transaction, the director owned 3,792,171 shares in the company, valued at approximately $16,495,943.85. This represents a 30.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George Magrath sold 9,475 shares of the firm's stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the sale, the chief executive officer directly owned 1,731,869 shares of the company's stock, valued at approximately $5,109,013.55. This trade represents a 0.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,729,331 shares of company stock worth $7,481,629 in the last ninety days. 11.70% of the stock is currently owned by corporate insiders.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts, improving its projected Q4 2026 EPS to a loss of $0.09 from a loss of $0.14 and its FY2026 estimate to a loss of $1.03 from a loss of $1.18. The firm also raised its FY2027 forecast to a loss of $0.40 from a loss of $0.46.
• Positive Sentiment: Analysts project a potential transition to profitability. HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline Capital Markets expects significantly higher FY2030 EPS of $0.62. These longer-term estimates may support investor optimism about Opus Genetics’ pipeline and commercial prospects.
• Positive Sentiment: HC Wainwright maintained a Buy rating and an $8.00 price target. Against the stock’s recent opening price of $3.88, the target implies substantial potential upside, although it depends on the company meeting distant earnings projections.
• Neutral Sentiment: Short-interest data provided no meaningful signal. Reported short interest was zero shares as of August 11, matching the prior period, with a zero-day short-interest ratio. However, the reported percentage change was listed as “NaN,” indicating unreliable or incomplete data.
• Negative Sentiment: Opus Genetics is still expected to report substantial losses in the near term. HC Wainwright estimates EPS of negative $1.03 for FY2026 and negative $0.16 for FY2028, while the broader consensus remains at negative $1.09 for the current fiscal year. The company also has a history of heavy losses and limited revenue, increasing execution and financing risks.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source